213 related articles for article (PubMed ID: 16927184)
1. Surface crystallization of indomethacin below Tg.
Wu T; Yu L
Pharm Res; 2006 Oct; 23(10):2350-5. PubMed ID: 16927184
[TBL] [Abstract][Full Text] [Related]
2. Fast surface crystallization of amorphous griseofulvin below T g.
Zhu L; Jona J; Nagapudi K; Wu T
Pharm Res; 2010 Aug; 27(8):1558-67. PubMed ID: 20414704
[TBL] [Abstract][Full Text] [Related]
3. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state.
Crowley KJ; Zografi G
Pharm Res; 2003 Sep; 20(9):1417-22. PubMed ID: 14567636
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug-polymer mixtures.
Priemel PA; Laitinen R; Barthold S; Grohganz H; Lehto VP; Rades T; Strachan CJ
Int J Pharm; 2013 Nov; 456(2):301-6. PubMed ID: 24012867
[TBL] [Abstract][Full Text] [Related]
5. [Microcosmic mechanisms of amorphous indomethacin crystallization and the influence of nano-coating on crystallization].
Hui OY; Yi T; Zheng Q; Liu F
Yao Xue Xue Bao; 2011 Jun; 46(6):707-12. PubMed ID: 21882533
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulation of amorphous indomethacin.
Xiang TX; Anderson BD
Mol Pharm; 2013 Jan; 10(1):102-14. PubMed ID: 23116319
[TBL] [Abstract][Full Text] [Related]
7. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin.
Hédoux A; Paccou L; Guinet Y; Willart JF; Descamps M
Eur J Pharm Sci; 2009 Sep; 38(2):156-64. PubMed ID: 19591926
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions.
Xiang TX; Anderson BD
J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486
[TBL] [Abstract][Full Text] [Related]
9. Fast surface crystallization of molecular glasses: creation of depletion zones by surface diffusion and crystallization flux.
Hasebe M; Musumeci D; Yu L
J Phys Chem B; 2015 Feb; 119(7):3304-11. PubMed ID: 25607221
[TBL] [Abstract][Full Text] [Related]
10. Origin of enhanced crystal growth kinetics near Tg probed with indomethacin polymorphs.
Wu T; Yu L
J Phys Chem B; 2006 Aug; 110(32):15694-9. PubMed ID: 16898713
[TBL] [Abstract][Full Text] [Related]
11. Indomethacin: Effect of Diffusionless Crystal Growth on Thermal Stability during Long-Term Storage.
Svoboda R; Koutná N; Košťálová D; Krbal M; Komersová A
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838556
[TBL] [Abstract][Full Text] [Related]
12. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability.
Crowley KJ; Zografi G
J Pharm Sci; 2002 Feb; 91(2):492-507. PubMed ID: 11835208
[TBL] [Abstract][Full Text] [Related]
13. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the microcrystallinity of a drug substance, indomethacin, in a pharmaceutical model tablet by chemometric FT-Raman spectroscopy.
Okumura T; Otsuka M
Pharm Res; 2005 Aug; 22(8):1350-7. PubMed ID: 16078145
[TBL] [Abstract][Full Text] [Related]
15. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature.
Yoshioka M; Hancock BC; Zografi G
J Pharm Sci; 1994 Dec; 83(12):1700-5. PubMed ID: 7891297
[TBL] [Abstract][Full Text] [Related]
16. Surface-enhanced crystallization of amorphous nifedipine.
Zhu L; Wong L; Yu L
Mol Pharm; 2008; 5(6):921-6. PubMed ID: 19434917
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting surface crystallization of amorphous indomethacin by nanocoating.
Wu T; Sun Y; Li N; de Villiers MM; Yu L
Langmuir; 2007 Apr; 23(9):5148-53. PubMed ID: 17397203
[TBL] [Abstract][Full Text] [Related]
18. Melt Crystallization of Indomethacin Polymorphs in the Presence of Poly(ethylene oxide): Selective Enrichment of the Polymer at the Crystal-Liquid Interface.
Zhang J; Shi Q; Guo M; Liu Z; Cai T
Mol Pharm; 2020 Jun; 17(6):2064-2071. PubMed ID: 32298128
[TBL] [Abstract][Full Text] [Related]
19. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
20. Improved physical stability of amorphous state through acid base interactions.
Telang C; Mujumdar S; Mathew M
J Pharm Sci; 2009 Jun; 98(6):2149-59. PubMed ID: 18837038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
